Who can use Orserdu(Elacestrant)?
Elacestrant is a selective estrogen receptor degrader (SERD) that binds to and antagonizes estrogen receptor α (ERα), inducing its degradation via the proteasomal pathway to inhibit the proliferation of estrogen-dependent tumor cells.
Who can use Orserdu(Elacestrant)?
The drug demonstrates significant antitumor activity in ER-positive, HER2-negative advanced or metastatic breast cancer with ESR1 mutations, especially in cases resistant to previous endocrine therapies.
It is primarily indicated for postmenopausal women and adult men with ER-positive, HER2-negative advanced or metastatic breast cancer harboring ESR1 mutations, who have experienced disease progression after at least one line of prior endocrine therapy.
